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Abstract 
Background & Aims: We sought to identify factors predictive of liver transplantation or 
death in patients with Primary Sclerosing Cholangitis (PSC), and to develop and validate a 
contemporaneous risk score for use in a real-world clinical setting. 
Methods: Analysing data from 1001 patients recruited to the UK-PSC research cohort, we 
evaluated clinical variables for their association with 2- and 10-year outcome through Cox-
proportional hazards and C-statistic analyses. We generated risk scores for short- and long-
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term outcome prediction, validating their use in two independent cohorts totalling 451 
patients. 
Results: 36% of the derivation cohort were transplanted or died over a cumulative follow-up 
of 7,904 years. Serum alkaline phosphatase ≥2 4×ULN at 1 year post diagnosis, was 
predictive of 10-year outcome (HR=3.05, C=0.63, median transplant-free survival 63 versus 
108 months, p<0.0001), as was the presence of extra-hepatic biliary disease (HR=1.45, 
p=0.01).  We developed two risk scoring systems based upon age, values of bilirubin, 
alkaline phosphatase, albumin, platelets, presence of extra-hepatic biliary disease and 
variceal haemorrhage, which predicted 2- and 10-year outcome with good discrimination 
(C=0.81 and 0.80 respectively).  Both UK-PSC risk scores were well-validated in our external 
cohort, and out-performed the Mayo and APRI scores (C=0.75 and 0.63 respectively). Whilst 
heterozygosity for the previously validated HLA-DR*03:01 risk allele predicted increased risk 
of adverse outcome (HR=1.33, p=.001), its addition did not improve the predictive accuracy 
the UK-PSC risk scores. 
Conclusions:  Our analyses, based upon a detailed clinical evaluation of a large 
representative cohort of participants with PSC, furthers our understanding of clinical risk 
markers and reports the development and validation of a real-world scoring system to 
identify those patients most likely to die or require liver transplantation.  
 
 
Introduction 
 
Primary sclerosing cholangitis (PSC) is a chronic fibrosing cholestatic liver disease frequently 
associated with inflammatory bowel disease (IBD)(1).  Disease progression culminates in 
end-stage liver disease and a high likelihood of death without liver transplantation(2). 
Patients with PSC have up to 15% lifetime risk of developing cholangiocarcinoma, which 
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parallels their risk of colorectal cancer(1,3-5). Insights into disease pathogenesis are limited 
but genetic studies highlight the importance of the adaptive immune system, with the 
strongest genetic association found within the HLA locus(6-8). 
 
Clinical course is variable and efforts to individualise risk prediction are important for 
patients, clinicians and trials of experimental agents(9).  Existing studies suggest that various 
clinical factors may predict the risk of adverse outcome.  For example, elevated IgG4 
concentration is reportedly associated (although not robustly validated) with an increased 
risk of progression to cirrhosis(10,11).  Conversely, small-duct PSC confers an improved 
survival and lower risk of cholangiocarcinoma(12), as does a reduction in serum alkaline 
phosphatase (ALP) 1-2 years following diagnosis(13-15).  Using cut-offs previously defined as 
stratifiers of risk in small bile duct disease primary biliary cholangitis (PBC), two studies have 
confirmed the independent prognostic value of ALP in PSC cohorts(13,14).  However many 
studies evaluating risk prediction models in PSC have been limited by sample size, tertiary 
centre recruitment bias, failure to control for the interaction of variables with one another 
and lack of validation(16).   With the exception of the revised Mayo Clinic model, prior 
prognostic models include histological staging(17-21). Whilst it is not unexpected that 
histology is a predictor of outcome (surrogates of liver fibrosis e.g. enhanced liver fibrosis 
score (ELF) and transient elastography perform equally well(22,23)), a simpler prognostic 
scoring is warranted. The revised Mayo Clinic model published in 2000, was designed to 
predict short-term survival within the proceeding 4 years and does not predict the need for 
transplantation(21).  Updated scoring systems such as the Amsterdam-Oxford model are 
designed to predict PSC-related death and liver transplant but demonstrate only moderate 
predictive power (C=0.68), likely to be explained by limited study-cohort size(24).  
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Given our ability to capture the clinical characteristics of a large, clinically representative, 
cohort of patients with PSC through the United Kingdom NIHR Primary Sclerosing 
Cholangitis (UK-PSC) Rare Disease Translational Research Cohort, we sought to describe the 
clinical course of PSC and to identify clinical and genetic features early in disease course that 
are associated with increased risk of transplantation or death.   In doing so, our subsequent 
internationally-validated findings provide clinically meaningful approaches to individualised 
risk prediction. 
 
Methods 
 
Study Design 
Using data from patients recruited to the UK-PSC research cohort (www.uk-psc.com) we 
evaluated participants with PSC who were ≥18 years of age with PSC incident or prevalent 
between August 1, 2008 and March 31, 2015, including liver transplant recipients who had 
undergone transplantation for PSC at any point before March 31, 2015.  Participants were 
recruited from throughout the UK across a research network of 155 collaborating National 
Health Service (NHS) Trusts, including nearly every hospital providing general or specialist 
hepatology services in the UK, excluding Northern Ireland.  
 
Inclusion criteria were based upon accepted diagnostic criteria for PSC(25) and included the 
presence of cholestatic liver biochemistry tests with characteristic bile duct changes on 
either endoscopic retrograde cholangio-pancreatography (ERCP), magnetic resonance 
cholangio-pancreatography (MRCP) and/or liver histology.  In order to address the 
challenges faced outside clinical trials of comparing MR images, the distinction between 
intrahepatic and extrahepatic biliary disease was determined by team review of local 
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radiographic reports of cholangiographic imaging, as opposed to single expert review.  
Involvement of first order bile ducts (right or left main hepatic duct) and/or common bile 
duct at cholangiography were classified as extrahepatic biliary disease, as opposed to their 
absence being classified as intrahepatic biliary disease. Exclusion criteria included congenital 
abnormalities of the biliary tree, previous biliary surgery likely to cause secondary sclerosing 
cholangitis, primary bile duct carcinoma, HIV cholangiopathy, PBC, positive anti-
mitochondrial antibody, hepatic sarcoidosis and drug-induced liver injury. 
 
The study was conducted in accordance with the guidelines of the Declaration of Helsinki 
and the principles of good clinical practice. All participants provided written informed 
consent.  Multi-regional ethics committee (MREC) approval was granted by the 
Cambridgeshire 4 National Ethics committee (MREC Number 08/45/008) and by the 
research and development department of each collaborating hospital. 
 
Data Capture 
Data were collected onto pre-specified questionnaires through systematic review of case 
notes between March 31, 2013 and March 31, 2015.  Data included patient demographics, 
diagnostic cholangiography/histology reports, serial biochemistry at diagnosis (t0), 1-year 
following diagnosis (t1) and 2-years following diagnosis (t2), IBD status, concomitant 
autoimmune disease, use of ursodeoxycholic acid (UDCA), development of malignancy or 
liver decompensation, and progression to transplantation or death.  74% of all data was 
collected by the lead clinician researcher (EG) during site visits to each hospital, and 
completed questionnaires reviewed by a second clinician researcher for accuracy and 
missing data.  The remaining 26% of data was collected by the responsible clinician or 
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research nurse at each hospital site, and reviewed by the lead clinician researcher (EG) upon 
return.  Where patients were under the care of more than one hospital (e.g. a transplant 
centre and a general hospital), the questionnaire was sent sequentially to each hospital to 
ensure complete data capture.  Missing or inaccurate data were systematically queried with 
the clinician who had completed the questionnaire to ensure complete and accurate data 
capture. Data that passed quality control were uploaded into a bespoke secure database. 
Study Entry and Outcome 
 
We calculated the time from PSC diagnosis to outcome event. t0 was defined as the date of 
first cholangiographic imaging or liver biopsy demonstrating PSC.  The first primary endpoint 
was liver transplantation, chosen as an important hard outcome for which a definitive time 
point is easily available.  In the context of liver disease, it can be difficult to accurately define 
deaths solely related to liver disease, therefore the second primary endpoint of all-cause 
mortality was chosen as the most encompassing term that would include all liver related 
deaths.  Participants who did not reach an endpoint were censored at the date of their most 
recent blood tests or follow-up.  To ensure capture of all outcome events, we utilised the 
fact that every UK patient has a unique NHS number which ensures that clinical coding is 
linked across primary, secondary and tertiary care.  This practice, in place throughout the 
40-year study follow-up duration, ensures that the risk of missed events was minimal, and 
did not bias the analysis. 
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Explanatory Variables 
We considered variables for their association with outcome and inclusion in the risk score, 
based upon clinical relevance or pre-existing evidence.  To account for variability in the 
measurement of laboratory investigations, alkaline phosphatase (ALP) was taken as a ratio 
of the upper limit of normal range (ULN) for the reporting laboratory.  Other laboratory 
measures used the following standard units of measurement; haemoglobin (Hb) g/l, platelet 
count (Plts) ×109/l, albumin (Alb) g/l, bilirubin (Bili) μ o / . 
 
Clinical data analysis  
We calculated and reported descriptive statistics as numbers or percentages. Variables with 
>40% missing data were excluded from further analysis. For this reason, the following 
variables were omitted from the analysis; INR, AST, IgG subclasses and date of first hepatic 
decompensation (ascites, hepatic encephalopathy, jaundice).  Time-to-event analysis was 
conducted using Cox's proportional hazards model, ensuring at least 10 events per risk 
factor included in the model(26).  To facilitate accurate risk prediction, events were 
truncated at 10 years of follow-up.  To ensure sufficient variation within the dataset, 
categorical variables were only considered if the categories had >5% of the cohort in each 
category.  Variables present in <5% of the cohort and thus excluded from the analysis were; 
smoking status and variceal haemorrhage at t0.   
 
We performed unadjusted/univariate analysis on the raw dataset to demonstrate 
associations between risk factors and outcome.  To account for missing data, we performed 
multivariable imputation using iteratively chained equations, combined the results of ten 
imputed data sets using R bi ’   q   io  , and estimated the adjusted/multivariable model 
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using this imputed dataset.  We selected variables for the final risk score using backward 
elimination, with removal of risk factors not significant at the 10% level(27). Continuous 
variables were assessed for non-linear association using cubic splines. Variables 
demonstrating a linear association were included in a standard continuous fashion.  
Variables demonstrating a non-linear association were categorised using cubic splines and 
clinical judgement to allow for ease of interpretation.  
 
Alkaline Phosphatase 
We analysed the association between ALP at t1 and t2 with outcome, to determine the 
optimal threshold for predicting 10-year hazard of outcome.   ALP was divided into 
categorical variables from </≥0.5 to 4×ULN, with increments of 0.1.  We plotted each ALP 
cut-off against the hazard of reaching an endpoint. The optimal threshold for ALP was 
      i      i g H      ’  C     i  ic.   
 
Derivation of the UK-PSC Risk Scores 
We derived three separate risk scores, to determine the model with the best discrimination.   
The first was a score using t0 data to predict 10-year risk of outcome, the second a short-
term risk score using t0 data to predict two-year risk of outcome (RSST), and the third, a long-
term risk score using t0 and t2 data to predict 10-year risk of outcome (RSLT).  The RSLT 
included only those patients not reaching a primary endpoint within 2 years of diagnosis. 
The discrimination of each score w   co p       i g H      ’  C statistic.  Calibration curves 
for RSST and RSLT were generated by c    i g   ci    of          co p  i g      o   ’  
predicted with the observed rates in the cohort, estimated by the Kaplan-Meier curve.   
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Validation of the UK-PSC risk scores  
We used data from two external PSC patient cohorts, not included in the original analysis, to 
validate the UK-PSC Risk Scores; the first a national validation cohort, n=352, from two UK 
hospitals (Transplant centre Queen Elizabeth Hospital Birmingham, and non-transplant 
centre John Radcliffe Hospital, Oxford(24)) and the second, an international validation 
cohort from Norway (n=99).  Methods of validation cohort data collection were identical to 
the derivation cohort; retrospective data from individual auditing of electronic and paper 
case notes by clinician researchers followed by quality control.  Validation of the scoring 
system was performed by fitting a Cox-model to the validation cohort using the scoring 
system derived from the derivation cohort(28).  Further visual validation was performed by 
displaying Kaplan-Meier survival curves for risk groups in both cohorts(28).  Risk groups 
were defined by dividing the derivation cohort into four equal sized groups with increasing 
RSLT, and the validation cohort divided into four groups according to the same RSLT 
categories.  
 
Comparison of the UK-PSC score with existing scores 
We analysed the predictive ability of the modified Mayo risk score and AST:platelet ratio 
index (APRI) scores in both derivation and validation cohorts, comparing them to the UK-
PSC Ri   Sco      i g H      ’  C     i  ic   Both the Mayo and APRI score algorithms include 
aspartate aminotransferase (AST). However, in most UK hospitals, AST is not measured as 
part of standard liver biochemical tests.  AST was therefore not available for calculation of 
the Mayo risk or APRI scores. Other studies have demonstrated some equivalence of AST 
and ALT(29).  Using a subset of patients for which both AST and ALT data were available at 
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the same time points, we demonstrated the correlation and concordance between the two 
variables.  We then used ALT in place of AST in the calculation of the Mayo risk score and 
APRI scores.   
 
Genetic data analysis 
Prior genotyping was conducted using the Illumina Immunochip(7), a targeted genotyping 
array with dense marker coverage across 186 known disease loci from 12 immune-mediated 
diseases. We considered the following HLA risk alleles, known to be associated with PSC 
disease risk from GWAS studies(6, 7); HLA-B*08:01, and HLA-DRB1*03:01, 04:01, 07:01, 
13:01 and 15:01.  The association between HLA risk alleles and outcome were analysed 
using a test for trend across 0, 1 and 2 copies of each allele.  We also tested for association 
between significant risk alleles and important clinical variables.  After application of a 
Bonferroni correction, our threshold for statistical significance was p<0.008.  
 
All analyses were performed using Stata software (version 14.0/SE; StataCorp LP, College 
Station, TX).  This study was conducted and reported in accordance with TRIPOD statement 
for transparent reporting of a multivariate prediction model for individual prognosis or 
diagnosis(30).  
 
 
Results 
 
Cohort characteristics 
1749 patients were recruited to the UK-PSC cohort; 1252 questionnaires distributed and 
1131 returned. 130 were excluded following quality control (figure 1), leaving 1001 patients 
for analysis, recruited from 108 hospitals, including 7 transplant centres. 57% were 
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recruited from non-transplant centres.  The cohort (table 1) included 64% male sex, 
diagnosed at a median age of 46.8 years with median follow-up of 14.8 years (range 0.2-
40.4), censored at time of transplant.  44% had extrahepatic biliary disease and 72.5% had 
concomitant IBD, most commonly ulcerative colitis (80.4%) and 14.3% of the cohort had 
another autoimmune disease.  UDCA was prescribed for 58% of the cohort within the first 2 
years following diagnosis.  
 
35.7% of patients reached a primary endpoint over a cumulative follow-up period of 7,904 
years.  27.8% underwent liver transplantation at a median age of 47.0 years. 7.9% died 
without a transplant; 47.8% of all deaths were PSC-related.  The overall proportion of the 
cohort who were event-free at 2, 5 and 10 years was 92%, 82% and 64% respectively. 39% 
of men reached an outcome, compared to 29% of females (χ2 =10.07, p=0.002).  43% of 
those with extrahepatic biliary disease reached an outcome compared to 23% of those 
without (χ2 =40.6, p=0.00). Patients with extrahepatic biliary disease had a reduced median 
transplant-free survival compared to those without extrahepatic biliary disease (11.7 versus 
23 years). UDCA use in the first 2 years following diagnosis was not associated with 
outcome.  11% of patients developed a gastrointestinal cancer, most commonly colorectal 
(5.4%), followed by cholangiocarcinoma (3.3%).  
 
Serum Alkaline Phosphatase is associated with PSC outcome 
ALP data at t1 and t2 was available for 72% and 70% of the cohort respectively.  At both 
timepoints, elevated ALP was associated with an increased 10-year hazard of reaching an 
outcome (p=<0.001) (figure 2a and 2b).  There was a log-linear association between serum 
ALP and outcome, however for ease of interpretation we chose to categorise ALP using 
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cubic splines (supplementary figure 1).  At t1 the optimal threshold for predicting 10-year 
outcome was ALP≥2 4×ULN (HR=3 05, C=0.63) (figure 2c); where median transplant-free 
survival was 63 versus 108 months for those with ALP<2.4×ULN (p<0.0001 (log-rank test)) 
(figure 2e).  At t2, the optimal threshold for predicting 10-year outcome was ALP≥2 2×ULN 
(HR=3.05, C=0.66) (figure 2d), where median survival was 44 versus >96 months for those 
with a t2 ALP<2.2×ULN (p<0.0001 (log-rank test)) (figure 2f).   
 
Disease distribution is associated with outcome in PSC 
Cholangiographic data at t0 were available in 87.2% of the cohort.  Presence of extrahepatic 
biliary disease was associated with adverse outcome (HR=1.45 (CI 1.09,1.92), p=0.010).  
Patients without extrahepatic biliary disease had improved 10-year event-free survival, 
although >50% of both groups were event free at 10-years and thus median survival was not 
reached (supplementary fig 2).  
  
Derivation of a UK-PSC Risk Score 
Our first UK-PSC risk score used factors available at t0 to predict 10-year risk of outcome.  
Following multivariable analysis, 7 factors were included in the score; age at t0, bilirubin, 
ALP, albumin, haemoglobin, platelets and presence of extrahepatic biliary disease a t0 
(supplementary table 1) (C=0.78, shrinkage=0.94).  Our cohort demonstrated a high event 
rate (8%) within the first 2 years of diagnosis.  Therefore, to determine if variables 
predicting short- and long-term risk differed, we derived a short-term risk score (RSST), using 
variables at t0 to predict risk of outcome within 2 years following diagnosis; and a long-term 
risk score (RSLT), using variables from t2 to predict 10-year risk of outcome (see Box).  Mean 
serum ALT, platelet count and ALP ratio were all significantly reduced from t0 to t2 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
(supplementary table 2).  Both RSST and RSLT demonstrated improved predictive ability over 
the original model.  
 
Short-term UK-PSC Risk Score (RSST): Four variables at t0 were associated with 2-year 
outcome; bilirubin, albumin, haemoglobin and platelet count (table 2).  Based upon these 
coefficients, a prognostic model was developed to predict risk of death or liver 
transplantation by year 2 (C =0.81, shrinkage=0.92) (Box 1).  
 
Long-term UK-PSC Risk Score (RSLT): Seven variables at t2 were association with 10-year risk 
of outcome; age at diagnosis, bilirubin at t2, ALP at t2, albumin at t2, platelets at t2, presence 
of extrahepatic biliary disease at t0 and variceal haemorrhage by t2 (C=0.80, shrinkage=0.96) 
(table 3 and Box 1). Calibration of RSST and RSLT using predicted versus observed survival 
rates estimated by Kaplan-Meier curve demonstrated good correlation. The scores are 
available at http://www.uk-psc.com/riskscores. 
 
To define low- and high-risk disease groups according to RSLT, we divided the cohort into 4 
four equal quartiles. Event-free survival, plotted on a Kaplan-Meir survival curve (figure 3a) 
demonstrated observed event rates of 6.0%, 8.4%, 19.1% and 55.8% in the four respective 
risk groups.  Curves were generally well separated, although the model was less able to 
distinguish between the two lowest risk groups. RSLT defining the four risk groups is shown 
in supplementary table 3.  
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Validation of the UK-PSC scores  
We analysed the predictive ability of both risk scores in a separate national and 
international patient cohort.  In the respective national and international validation cohorts 
(table 1), 62.4% and 75.7% of the cohort were male, diagnosed at a median age of 47 and 39 
years, with 71% and 86% diagnosed with concomitant IBD.  The most notable differences 
between the derivation and validation cohorts were the shorter median follow-up (6 and 8 
years in the national and international cohorts, versus 14.8 years), higher death rate (25.3% 
and 21.2% versus 7.9%) and lower transplant rate (13.9% and 11.1% versus 27.8%).  
 
Both the RSST and RSLT were associated with outcome in the national validation cohort 
(p<0.001).  The slope of the Cox model for the RSST in the validation cohort was 1.09 which is 
not significantly different from 1, indicating the discrimination was preserved.  The slope for 
the RSLT was 1.36 (p=0.0071) which is significantly different from 1, suggesting that the score 
is more predictive of outcome in the validation than the derivation cohort.  In the 
international validation cohort, the lack of events within the first two years meant only the 
RSLT could be validated.  The RSLT was associated with outcome in the international 
validation cohort (p<0.001); the slope was 1.60 and not significantly different from 1 
(p=0.014), indicating preserved discrimination, although this was based upon only 37 
individuals.   
 
Further visual validation of the RSLT was performed by comparing Kaplan-Meier survival 
curves for the validation cohort according to the same four previously defined risk groups as 
the derivation cohort (figures 3b and 3a respectively).  Event rates were similar to the 
derivation cohort at 2.9%, 10.4%, 20.0% and 47.9% (supplementary table 3).  Both set of 
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four curves were quite well separated, confirming that the model had discrimination in both 
cohorts, however the model was less able to distinguish between the two intermediate risk 
groups in the validation cohort. 
 
Comparison of UK-PSC score with existing scores 
We compared the predictive accuracy of the Mayo and APRI scores to the RSST and RSLT in 
the imputed derivation dataset.  Based upon a subset of 170 patients from the validation 
cohort, for which both AST and ALT measurement were available for t0 and t2, there was 
strong correlation, (r = 0.94, p<0.0001) and strong concordance (c = 0.92, p<0.0001) 
between the two variables.  ALT was therefore used in place of AST for calculation of the 
Mayo and APRI scores.  In predicting 2-year outcome, the RSST out-performed the APRI and 
Mayo scores with C statistics of 0.81, 0.63 and 0.75 respectively. In predicting 10-year 
outcome the RSLT demonstrated an incremental improvement over the APRI and Mayo 
scores with C statistics of was 0.80, 0.59 and 0.79 respectively.   
 
We then compared the predictive accuracy of the Mayo and MELD scores to the RSST and 
RSLT in the validation dataset. In predicting 2-year outcome, the RSST out-performed the 
Mayo and MELD scores with C statistics of 0.81, 0.73 and 0.78 respectively.  In predicting 10-
year outcome the RSLT demonstrated a markedly improved predictive accuracy compared 
with Mayo and MELD with C statistics of 0.85, 0.69 and 0.70 respectively.  
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HLA risk alleles are associated with outcome 
HLA genotype was available for 635 patients.  27% and 9% of the cohort were heterozygous 
and homozygous for the HLA-DR*03:01 risk allele respectively.  Presence of this allele was 
associated with outcome in a dose-dependent manner (HR=1.33, CI 1.13, 1.58, p=0.001) 
(supplementary table 4). After testing for association between HLA-DR*03:01 and clinical 
characteristics at diagnosis, we found HLA-DR*03:01 risk alleles to be inversely correlated 
with mean age at diagnosis (no copies 47.6 years, heterozygote 46.6 years, homozygote 
40.8 years, p=0.007)(supplementary table 5).  Addition of the HLA-DR*03:01 risk allele to 
the risk score did not improve the discrimination of the model.  No association was 
observed with HLA-B*08, HLA-DR*04:01, 07:01, 13:01 or 15:01.   
 
 
Discussion 
Using a large cohort of 1001 patients from across the entire UK, including 57% recruited 
from non-transplant centres and thus representing the full spectrum of PSC disease severity, 
we provide important, externally validated clinical and genetic modelling, based upon 
readily available clinical factors for prediction of short and long-term outcome. Based upon 
presence of extrahepatic biliary disease at t0, age, bilirubin, ALP, albumin and platelets at t2 
and variceal haemorrhage by t2, we present a scoring system both of value in individual risk 
evaluation, as well as a potential mechanism to stratify recruitment to clinical trials.  
 
Our study confirms the importance of ALP as a prognostic indicator, both individually and as 
part of our RSLT. We demonstrate ALP<2.4×ULN and <2.2×ULN at 1 and 2 years following 
diagnosis, is associated with improved transplant–free survival.  Understanding the 
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behaviour of ALP as a biomarker in PSC is of interest, and parallels interest in PBC.  In PBC, 
dichotomous risk scores have C statistics of around 0.6, with the dynamic scores reporting C 
statistics of 0.8 and above(31, 32).  Whilst in PSC, serum ALP was not associated with short-
term outcome, the prognostic importance as longer-term predictor of clinical events is 
highlighted by its inclusion in our long-term risk score.  This may be explained by 
fluctuations in ALP in the early stages of diagnosis, which limit its prognostic value, and the 
rationale that short-term risk is driven by factors that measure cholestasis and portal 
hypertension.  Thus, when considering ALP in isolation, we chose to consider ALP at t1 and t2 
rather than t0, and used this to predict long-term rather than short-term risk.   In addition, 
our study demonstrated the poor prognostic impact of extrahepatic biliary disease, 
highlighting the importance of further study into cholangiographic monitoring in PSC.  
Whilst simple cholangiographic imaging used at diagnosis does carry meaningful prognostic 
data, improving cholangiographic evaluation remains important.  
 
We observed a high event rate (8%) within the first two years following diagnosis, 
suggesting there is a patient cohort who present late in disease course, or who experience 
rapidly progressive disease. Recognising this, we developed separate risk scores for short- 
(RSST) and long-term (RSLT) prediction, the key differences between which are that the 
former includes only laboratory parameters (bilirubin, albumin, haemoglobin and platelets), 
suggesting that intrinsic liver function is most important in predicting immediate outcome.  
Conversely the RSLT includes laboratory factors (bilirubin, albumin, platelets, ALP) in addition 
to variceal bleeding and cholangiographic disease distribution.  By using a dichotomous 
approach to risk stratification, we improved predictive utility from C=0.78 with our original 
score, to C=0.80 and 0.81 for short-term prediction and C=0.80 and 0.85 for long-term 
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prediction, in the derivation and validation cohorts respectively.  In practice, this would 
allow clinicians to recalculate risk at 2 years following diagnosis for greater prognostic 
accuracy.   
 
There must remain a risk of better performance of our model, due to data fitting, a risk we 
acknowledge. We tried to address this by comparing our risk scores existing scores, 
including the Mayo score.  W i    w    co fi       M  o  i    co  ’  prognostic value, it 
was out-performed by our RSST and RSLT, which also confer several other advantages.  Whilst 
the Mayo score is based upon the parameters age, bilirubin, AST, variceal bleeding and 
albumin, the UK-PSC risk scores consider more aspects of disease progression including age, 
ALP, albumin, platelets, extra-hepatic biliary disease and variceal haemorrhage.  The Mayo 
risk score predicts only 4-year risk of all-cause mortality and does not provide a strong long-
term predictor of outcome. It performs best in patients with end-stage liver disease and 
does not consider the important outcome of liver transplantation.  In comparison, the 
dichotomous UK-PSC risk scores predicts short- (2-year) and long-term (10-year) outcomes, 
ensuring that predictive ability is as good for those patients presenting with early, as well as 
late stage liver disease and includes the important outcome of liver transplantation in 
addition to all-cause mortality.   
 
We found one previously validated HLA risk allele to be an important in predictor of disease 
outcome: HLA-DR*03:01, demonstrated a gene-dose effect; but notably the addition of 
HLA-DR*03:01 did not improve the predictive ability of our prognostic score. When 
considering effect size, HLA-DR*03:01 had an adjusted hazard ratio of 1.33 (CI 1.13,1.58, 
p=0.001) for outcome, more comparable to that of extrahepatic biliary disease or ALP, in 
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comparison with the strongest associated clinical variable, bilirubin which had an adjusted 
odds ratio of 3.96 (CI 2.4,6.9, p<0.001). 
 
A strength of our cohort is the representative nature of the participants, notably identifying 
low-risk as well as high-risk patients.  In our study, we can confidently   fi     ‘ ow  i  ’ 
disease group according to RSLT (patients with a RSLT of <-2.02 had <10% chance of an event 
by 10 years follow up)       ‘ ig   i  ’ g o p (patients with RSLT score -0.81 < RSLT < 2.74 
had ~ 50% chance of an event by 10 years). Both UK-PSC Risk scores (http://www.uk-
psc.com/riskscores) were well validated in a separate patient cohort.  The major difference 
between derivation and validation cohorts was a lower death and higher transplant rate in 
the former.  There are some biases in our derivation cohort, reflective of ascertainment 
processes. Recruitment to the UK-PSC derivation cohort was retrospective through 
prevalent case ascertainment. Recruitment was therefore inherently biased towards those 
patients with or without transplant, who survived to 2008 to be recruited to the study, 
compared to those patients who died before 2008.  A further function of this, is the low 
prevalence of cholangiocarcinoma (3.3%) in our cohort.  Retrospective cohort recruitment is 
not well suited to capturing data on outcome markers associated with very poor survival; 
nearly 50% of all PSC-associated cholangiocarcinomas manifest within 2 years of PSC 
diagnosis(2).  Despite these limitations, the UK-PSC risk scores were nationally and 
internationally well-validated in two external cohorts, lending weight to their importance as 
robust prognostic models.   
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
Retrospective data collection also carries the inherent drawback of incomplete data 
collection.  Not surprisingly, rates of missing data were higher for patients diagnosed many 
years previously. Given that it was only related to the year of diagnosis, we considered 
these data to be missing at random, and used imputation to improve the validity of the 
results.  Whilst a date of diagnosis before 1990 was associated with an improved transplant-
free survival, removal of these patients from the analysis, did not alter the strength of the 
reported associations with either short- or long-term outcome, and thus they were retained 
for the purpose of statistical power.  
 
In our study, we did not observe any difference in outcome according to sex or subtype of 
IBD.  The evidence fo  f        x     C o  ’   i      co f   i g   f vo   b   o  co   i  
patients with PSC has only been robustly supported by evidence from one large study 
including more than 7000 patients with PSC(2).  It is therefore likely that with a total sample 
size of 1452, our study was underpowered to detect any such an effect.  Further studies of 
even larger cohorts, adjusted for multiple factors, are needed to confidently validate this 
finding.  In particular, this necessitates careful consistent classification of PSC-associated 
IBD.  
 
We chose the endpoints of all-cause mortality and liver transplantation rather than hepatic 
decompensation (e.g. ascites and hepatic encephalopathy), because they provide a 
definitive and easily identifiable event and time of event, necessary for a retrospective 
observational study. In comparison, hepatic decompensation can remain undiagnosed for 
several months and the precise date of diagnosis remain subjective; such issues are less 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
relevant in well-designed clinical trial/prospective cohort settings where such endpoints are 
clearly meaningful and can be collected robustly.  Arguably there are challenges with our 
chosen endpoints due to possible variation in clinical practice and outcomes over time. 
Indeed, it must always be acknowledged that changes in disease course over the time 
period of a study needed to evaluate outcomes, is a potential confounding factor. 
Evaluating such changes can be hard; contemporaneous reference literature may, for 
example, not reflect clinical changes to a disease manifestation, but reporting and 
investigative practices. Despite PSC being infrequent overall, and the difficulty in recruiting 
large cohorts for the development of well-powered evaluations, we have collated a unique 
dataset capturing ~15% of the total UK PSC population, with substantial power to evaluate 
all-cause mortality and transplantation.  Whilst accepting limitations inherent to our 
approach there is no evidence to date, that PSC outcomes have varied over the time course 
of our study, simply on the basis of era, and recent data reporting liver transplant practice in 
the UK additively supports this(33). Our approach is importantly, of significance to clinicians 
as the risk score analyses best reflect collective real-world clinical practice, with a focus on a 
spectrum of patients reflective of the disease, and a study design that through large cohort 
size, accommodates the weaknesses introduced by non-trial based uniform evaluation and 
data capture.  
 
In conclusion, our analyses based on a detailed clinical evaluation of a large 
representative cohort of participants with PSC has furthered our understanding of clinical 
risk markers for predicting outcome in patients with PSC.  
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Figure legends 
Figure 1: Study flow diagram 
 
Figure 2: Predictive value of Alkaline Phosphatase and outcome 
a) Association between alkaline phosphatase (as ratio of ULN) at year 1 and hazard of 
reaching a clinical endpoint within 10 years, with 95% CI b) Association between alkaline 
phosphatase (as ratio of ULN) at year 2 and hazard of reaching a clinical endpoint within 10 
years, with 95% CI c) H      ’  C- statistic per ALP cut-point at year 1 for 10-year hazard of 
outcome d) H      ’  C- statistic per ALP cut-point at year 2 for 10-year hazard of outcome e) 
Kaplan Meier survival curve for transplant-free survival in patients with ALP2.4×ULN (blue 
line) versus ALP>2.4×ULN (red line) at 1 year following diagnosis (0 = 12 months post 
diagnosis) f) Kaplan Meier survival curve for transplant-free survival in patients with 
ALP2.2×ULN (blue line) versus ALP>2.2×ULN (red line) at 2 years following diagnosis (0 = 24 
months post diagnosis) 
 
Figure 3: Kaplan-Meir survival curves for 4 risk groups  
Risk group 1; RSLT > -2.019879 (blue line), risk group 2; -1.463874 <RSLT < -2.019879 (red 
line), risk group 3; -0.8146346 <RSLT < -1.463874 (green line), risk group 4; 2.737384 <RSLT < -
0.8146346 (orange line). a) Derivation cohort Kaplan-Meir survival curves for 4 risk groups 
b) Validation cohort Kaplan-Meir survival curves for 4 risk groups  
 
 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
Table 1: Demographics of the UK-PSC derivation cohort (n=1001), national validation cohort 
(n=352) and international validation cohort (n=99)  
  
Derivation Validation Cohorts 
 Variable 
Cohort 
n=1001 (%) 
National 
n=352 (%) 
International 
n=99 (%)  
Demographics Male 63.8 62.4 75.7 
  Mean age at diagnosis (yrs)   46.8   45.0 35.0 
  Median age at transplant   47    47.0  39.0 
  Median follow-up (yrs)   14.8 6.0   8.0 
Disease Distribution Extrahepatic biliary disease present 44.1 47.8 33.3 
IBD IBD  72.5 71.0 86.0 
    Ulcerative Colitis 80.4 73.6 77.6 
    Crohns Colitis 14.2 10.7 15.3 
    Indeterminate Colitis   5.4 3.2   7.1 
Autoimmune disease Autoimmune disease 14.3 - - 
    Thyroid disease   6.9 - - 
    Rheumatoid arthritis   2.3 - - 
    Coeliac Disease   2.0 - - 
   Other   6.2 - - 
Smoking status Never smoked 53.2 - - 
 Ex-smoker 26.5 - - 
 Current smoker   3.7 - - 
Events Total events  35.7 39.2 32.3 
  Transplants 27.8 13.9 11.1 
  Deaths (all-cause)   7.9 25.3   21.2 
Cancers GI Cancer 10.7 - - 
   Colorectal Ca   5.4 - - 
    Cholangio Ca   3.3 - - 
    GB Cancer   1.3 - - 
    HCC   0.6 - - 
    Pancreatic Cancer   0.1 - - 
UDCA use  Taking UDCA at year 2 57.8 - - 
 Median dose (mg/kg) 11.4 - - 
 Range (mg/kg) 2.2-46.8 - - 
 
 
PSC; Primary Sclerosing Cholangitis, IBD; inflammatory bowel disease, UDCA; Ursodeoxycholic acid, GI; 
Gastrointestinal, GB; gallbladder, HCC; Hepatocellular carcinoma, Ca; cancer, UDCA; ursodeoxycholic acid 
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Table 2: Univariate analysis using un-imputed data and multivariate analysis using imputed 
data, of factors at diagnosis associated with 2-year risk of transplantation or death 
 
 Univariate Analysis Multivariate Analysis 
Factor HR (95% CI) p-value HHR (95% CI) p-value 
Female 0.88 (0.54,1.42)   0.596     
Age at diagnosis 1.01 (1.00,1.03)   0.126   
Extrahepatic biliary disease 1.30 (0.77,2.21)   0.332   
IBD presence 1.09 (0.49,2.44)   0.832   
   UC 1.12 (0.67,1.89)   0.665   
   CD 0.39 (0.12,1.31)   0.127   
   Indeterminate colitis 1.38 (0.47,4.03)   0.560   
Autoimmune disease 0.90 (0.46,1.75)   0.757   
Smoker 1.22 (0.74,2.02)   0.426   
Bilirubin (μmol/l)     
   35 -49 4.03 (1.36,11.98)   0.012 2.11 (0.74,5.96)   0.159 
   50+ 14.12 (7.89,25.3) <0.001 5.02 (2.76,9.13) <0.001 
ALP (ratio of ULN)     
  1.5 - <2.5 1.25 (0.49,3.17)   0.634   
  2.5+ 2.64 (1.35,5.17)   0.005   
ALT (IU/l)* 1.02 (0.98,1.05)   0.331   
Albumin (g/l) 0.87 (0.84,0.90) <0.001 0.94 (0.90,0.99)   0.011 
Haemoglobin (g/l)** 0.98 (0.97,0.99) <0.001 0.99 (0.97,1.00)   0.095 
Platelets group (×10
9
/l)     
  150 - 199 0.23 (0.08,0.72)   0.011 0.62 (0.26,1.48)   0.283   
  200 - 399 0.22 (0.11,0.45) <0.001 0.50 (0.25,0.98)   0.045   
  400+ 0.32 (0.13,0.78)   0.012 0.38 (0.15,0.98)   0.046   
Eosinophils (×10
9
/l) 1.10 (0.89,1.36)   0.368   
Sodium (mmol/l) 0.89 (0.82,0.98)   0.015   
Creatinine >120 (µmol/l) 4.21 (1.66,10.68)   0.002   
IgG (g/l)*  1.08 (0.93,1.25)   0.313   
 
 
IBD; Inflammatory bowel disease, UC; Ulcerative colitis, CD; Crohns disease, ALP; Alkaline Phosphatase ALT; Alanine Transaminase, IgG; 
immunoglobulin G, *denotes hazard ratio for a 10 unit change, **denotes hazard ratio for a 1 unit change 
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Table 3: Univariate analysis using un-imputed data and multivariate analysis using  imputed 
data, of factors at year 2 associated with 10-year risk of transplantation or death 
 
 Univariate Analysis Multivariate Analysis 
Factor HR (95% CI) p-value HHR (95% CI) p-value 
Female 0.81 (0.60,1.10)   0.181    
Age at diagnosis 1.01 (1.00,1.03)   0.005 1.03 (1.01,1.04)  <0.001 
Extrahepatic biliary disease 1.95 (1.42,2.69) <0.001 1.70 (1.15,2.48)    0.008 
IBD 0.91 (0.59,1.38)   0.646   
   UC 0.92 (0.70,1.22)   0.558   
   CD 0.68 (0.41,1.11)   0.122   
   Indeterminate colitis 1.28 (0.71,2.31)   0.416   
Autoimmune disease 1.27 (0.88,1.83)   0.200   
Smoker 0.96 (0.70,1.32)   0.790   
Bilirubin (μmol/l)     
   35 -49 6.77 (3.87,11.85) <0.001 3.31 (1.65,6.62)    0.001 
   50+ 7.92 (5.62,11.18) <0.001 3.96 (2.37,6.62)  <0.001 
ALP (ratio of ULN)     
  1.5 - 2.4 1.75 (0.98,3.15)   0.061 1.50 (1.09,2.30)    0.015 
  2.5+ 1.40 (1.04,1.88)   0.025 1.57 (1.12,2.52)    0.011  
ALT (IU/l)**  1.05 (1.03,1.08) <0.001   
Albumin (g/l) 0.88 (0.85,0.90) <0.001 0.93 (0.90,0.96)  <0.001 
Haemoglobin (g/l)** 0.75 (0.69,0.81) <0.001      
Platelets group (×10
9
/l)     
  150 - 199 0.35 (0.20,0.60) <0.001 0.58 (0.31,1.10)    0.092 
  200 - 399 0.29 (0.20,0.43) <0.001 0.60 (0.40,0.91)    0.016 
  400+ 0.32 (0.17,0.60) <0.001 0.46 (0.23,0.92)    0.028 
Eosinophils (×10
9
/l) 0.81 (0.52,1.29)   0.380   
Sodium (mmol/l) 0.90 (0.96,0.93) <0.001   
Creatinine >120 (µmol/l) 0.66 (0.21,2.07)   0.474   
IgG (g/l)**  1.01 (0.92,1.12)   0.774   
UDCA use 0.96 (0.72,1.28)   0.795   
Variceal bleed by yr 2 5.97 (2.93,12.16) <0.001 2.76 (1.14,6.66)    0.024 
 
 
**Denotes hazard ratio for a 10 unit change  
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Box 1: 
 
Short-term UK-PSC Risk Score (RST) = 0.745(Bili_t0 Group 1 [0/1] + 1.613(Bili_t0 Group 2 
[0/1]) – 0.061(Alb_t0 [g/l]) - 0.012(Hb_t0 [g/l]) -0.476(Plts_t0 Group 1 [0/1]) – 0.698(Plts_t0 
Group 2 [0/1]) -0.962(Plts_t0 Group 3 [0/1]).  
 
Long-term UK-PSC Risk Score (RSLT) = 0.026(Age_t0[yrs]) + 1.197(Bili_t2 Group 1 [0/1]) + 
1.38(Bili_t2 Group 2 [0/1]) + 0.4(ALP_t2 Group 1 [0/1]) + 0.45(ALP_t2 Group 2 [0/1]) –
0.07(Alb_t2[g/l]) –0.543(Plts_t2 Group 1) – 0.503(Plts_t2 group 2) – 0.768(Plts_t2 Group 3 
[0/1]) + 0.524(disease type_t0 [0/1]) + 1.014(variceal bleed_t2 [0/1]).    
 
Bili_t0/t2  group 1; 0= Bili_t0<35 μmol/l or >50 μmol/l, 1= 35 to ≤ 50 μmol/l 
Bili_t0/t2  group 2; 0=Bili_t0 < 50 μmol/l, 1=Bili_t0 ≥50 μmol/l  
Plts_t0/t2 group 1; 0=Plts_t0<150×10
9/l, or ≥200×109/l, 1= Plts_t0 150 to <200×10
9/l  
Plts t0/t2 group 2; 0=<200 or ≥ 400×10
9/l, 1= 200 to <400×109/l 
Plts_t0/t2 group 3; 0=<400×10
9/l, 1= ≥ 400×109/l 
ALP_t2 group 1; 0=ALP_t2<1.5×ULN or ≥2.5×ULN, 1=1.5 to <2.5,  
ALP_t2 group 2; 0= ALP_t2<2.5×ULN, 1=≥2.5×ULN,  
Disease type_t0; 0=no extrahepatic biliary disease, 1=presence of extrahepatic biliary 
disease Variceal bleed_t2; 0= no bleed by t2, 1=bleed by t2.   
 
Predicted survival rate at time t = (Baseline survival at time t) ^ exp (RSST or RSLT),  
 
RSST baseline survival at time t; 1 year: 0.0096612, 2 years: 0.0001109 
RSLT baseline survival at time t; 1 year: 0.9218476, 2 years: 0.8227174, 5 years: 0.7070919, 
8 years: 0.2771266.  
 
Example 
An individual aged 47 and with no evidence of extra-hepatic disease at diagnosis with the 
following biochemistry at t0: Bili 37μ o / , Alb 34 g/l, Hb 130 g/l and Plts 245×10
9/l, and the 
following biochemistry at t2: Bili 24μ o / , ALP 2×ULN, Alb 30 g/l, Plts 152×10
9/l and no 
variceal bleed by t2, would score would score: RSST= (0.745 ×1) – (0.061 ×34)-(0.012 ×130)- 
(0.698×1)= -3.587.  Predicted event free survival rate at 2 years = (0.0001109)^exp (-3.587)= 
0.78= 78%.  RSLT=(0.026 × 47) + 0.403 + (- 0.07 × 30)– 0.543 = -1.018.  Predicted event free 
survival rate at 5 years = 0.707 ^ exp (-1.047) = 0.885 =88.5% .  
 
The UK-PSC risk scores are available at http://www.uk-psc.com/riskscores 
 
 
 
 
